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Background
Existing medical evidence regarding cytokine profile in
both plasma and synovial fluid support significant
changes in Juvenile Idiopathic Arthritis (JIA) patients.
Aim
To evaluate the possible role of TNF-a in monitoring
disease activity in JIA.
Methods
In a 2-year prospective study, TNF-a levels were mea-
sured using ELISA in 63 serum samples and 4 synovial
f l u i d( S F )s a m p l e s ,f o r4 0J I Ap a t i e n t s .T h ec o n t r o l
population consisted of 18 healthy children. The data
were correlated with disease activity and severity (quan-
tified with JADAS27 score) and also with several bio-
markers of inflammation.
Results
TNF-a was measurable in 39 serum samples and in all
SF samples. Only 19% of serum samples had greater
TNF-a levels than controls. The most elevated levels of
serum TNF-a were found in patients during clinical
remission with Etanercept. In one patient with seroposi-
tive polyarticular disease, Etanercept administration for
6 months resulted in important elevation of serum
TNF-a, regardless of clinical improvement. SF levels
were significantly higher than simultaneously serum
levels (p=0.02), with no significant differences among
oligoarticular and polyarticular forms of JIA. We found
no correlation of serum TNF-a values with disease
activity and severity. In our patients the circulating
TNF-a values were significantly correlated only with
hemoglobin levels (r=-0.30; p=0.04) in the oligoarticular
group and with serum Immunoglobulin G (r=0.70;
p<0.01) in the systemic group.
Conclusions
We found no correlation of serum TNF-a values with
disease activity and severity. Upon treatment with Eta-
nercept, although many JIA patients reached remission
on medication, they developed increased circulating
TNF-a levels.
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